Search Results

The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.

Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.

Scorpion Therapeutics, Inc. announced leadership changes intended to position the Company for its next phase of growth, including the appointment of Adam Friedman, M.D., Ph.D., as Chief Executive Officer.

Scorpion Therapeutics, Inc announced preclinical data for STX-241, an orally bioavailable, highly selective, central nervous system -penetrant and potentially best-in-class fourth generation epidermal growth factor receptor tyrosine kinase inhibitor designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation in non-small cell lung cancer.

Scorpion Therapeutics, Inc. (“Scorpion”) today announced an exclusive collaboration and license agreement for the co-development of STX-721 and STX-241, two candidates in Scorpion’s franchise of highly-selective, next-generation mutant epidermal growth factor receptor (“EGFR”) inhibitors.

Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in New York City.

Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine, today announced the appointment of Michael Streit, M.D., M.B.A as the Company’s first Chief Medical Officer (“CMO”).